Novavax, Inc. NVAX shares are trading higher by 3.5% at $246 following recent favorable commentary on its COVID-19 vaccine by President Biden and the company receiving an additional $147.3 million as part of Operation Warp Speed to develop a COVID-19 vaccine. The stock could also be gaining in anticipation of upcoming vaccine data.
Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly-owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.